相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Risk Assessment in Solitary Fibrous Tumor of the Uterine Corpus: Report of a Case and Systematic Review of the Literature
Laura Ardighieri et al.
INTERNATIONAL JOURNAL OF SURGICAL PATHOLOGY (2022)
The Immunohistochemical Expression of Programmed Death Ligand 1 (PD-L1) Is Affected by Sample Overfixation
Angels Barbera et al.
APPLIED IMMUNOHISTOCHEMISTRY & MOLECULAR MORPHOLOGY (2021)
Immune checkpoint-related serum proteins and genetic variants predict outcomes of localized prostate cancer, a cohort study
Qinchuan Wang et al.
CANCER IMMUNOLOGY IMMUNOTHERAPY (2021)
Programmed cell death-ligand 1 assessment in urothelial carcinoma: prospect and limitation
Kyu Sang Lee et al.
JOURNAL OF PATHOLOGY AND TRANSLATIONAL MEDICINE (2021)
Association between CD8 and PD-L1 expression and outcomes after radical prostatectomy for localized prostate cancer
Cecile Vicier et al.
PROSTATE (2021)
Mitotically Active Cellular Fibroma of the Ovary Recurring After the Longest Interval of Time (16 yr): A Challenging Case With Systematic Literature Review
Rocco Olivadese et al.
INTERNATIONAL JOURNAL OF GYNECOLOGICAL PATHOLOGY (2021)
Immune response drives outcomes in prostate cancer: implications for immunotherapy
Jialin Meng et al.
MOLECULAR ONCOLOGY (2021)
Prostate cancer C5a receptor expression and augmentation of cancer cell proliferation, invasion, and PD-L1 expression by C5a
Ryuji Imamura et al.
PROSTATE (2021)
PD-L1 immunohistochemistry in non-small-cell lung cancer: unraveling differences in staining concordance and interpretation
Cleo Keppens et al.
VIRCHOWS ARCHIV (2021)
What Do We Have to Know about PD-L1 Expression in Prostate Cancer? A Systematic Literature Review. Part 3: PD-L1, Intracellular Signaling Pathways and Tumor Microenvironment
Andrea Palicelli et al.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES (2021)
What Do We Have to Know about PD-L1 Expression in Prostate Cancer? A Systematic Literature Review. Part 4: Experimental Treatments in Pre-Clinical Studies (Cell Lines and Mouse Models)
Andrea Palicelli et al.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES (2021)
What Do We Have to Know about PD-L1 Expression in Prostate Cancer? A Systematic Literature Review. Part 5: Epigenetic Regulation of PD-L1
Andrea Palicelli et al.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES (2021)
Primary Pulmonary B-Cell Lymphoma: A Review and Update
Francesca Sanguedolce et al.
CANCERS (2021)
Klebsiella pneumoniae Chorioamnionitis: An Underrecognized Cause of Preterm Premature Rupture of Membranes in the Second Trimester
Maria Paola Bonasoni et al.
MICROORGANISMS (2021)
Systemic Mastocytosis Associated with Smoldering Multiple Myeloma
Magda Zanelli et al.
DIAGNOSTICS (2021)
Safety and Clinical Activity of Atezolizumab in Patients with Metastatic Castration-Resistant Prostate Cancer: A Phase I Study
Daniel P. Petrylak et al.
CLINICAL CANCER RESEARCH (2021)
Cell membrane and nuclear expression of programmed death ligand-1 in prostate needle biopsy tissue in prostate cancer patients undergoing primary radiation therapy
Kang Hee Shim et al.
UROLOGIC ONCOLOGY-SEMINARS AND ORIGINAL INVESTIGATIONS (2021)
Inter- and intra-tumor heterogeneity of metastatic prostate cancer determined by digital spatial gene expression profiling
Lauren Brady et al.
NATURE COMMUNICATIONS (2021)
N-cadherin inhibitor creates a microenvironment that protect TILs from immune checkpoints and Treg cells
Yi Sun et al.
JOURNAL FOR IMMUNOTHERAPY OF CANCER (2021)
How Can We Treat Vulvar Carcinoma in Pregnancy? A Systematic Review of the Literature
Andrea Palicelli et al.
CANCERS (2021)
Prognostic Significance of Gene Expression and DNA Methylation Markers in Circulating Tumor Cells and Paired Plasma Derived Exosomes in Metastatic Castration Resistant Prostate Cancer
Martha Zavridou et al.
CANCERS (2021)
Kingella kingae Intrauterine Infection: An Unusual Cause of Chorioamnionitis and Miscarriage in a Patient with Undifferentiated Connective Tissue Disease
Maria Paola Bonasoni et al.
DIAGNOSTICS (2021)
Immunohistochemical Biomarkers as a Surrogate of Molecular Analysis in Ovarian Carcinomas: A Review of the Literature
Giacomo Santandrea et al.
DIAGNOSTICS (2021)
Expression of immune checkpoints on circulating tumor cells in men with metastatic prostate cancer
Tian Zhang et al.
BIOMARKER RESEARCH (2021)
ShRNA-mediated silencing of PD-1 augments the efficacy of chimeric antigen receptor T cells on subcutaneous prostate and leukemia xenograft
Jing-E Zhou et al.
BIOMEDICINE & PHARMACOTHERAPY (2021)
Pembrolizumab with or without enzalutamide in selected populations of men with previously untreated metastatic castration-resistant prostate cancer harbouring programmed cell death ligand-1 staining: a retrospective study
Huanyi Lin et al.
BMC CANCER (2021)
Primary effusion lymphoma occurring in the setting of transplanted patients: a systematic review of a rare, life-threatening post-transplantation occurrence
Magda Zanelli et al.
BMC CANCER (2021)
Radium-223 Treatment Increases Immune Checkpoint Expression in Extracellular Vesicles from the Metastatic Prostate Cancer Bone Microenvironment
Ioulia Vardaki et al.
CLINICAL CANCER RESEARCH (2021)
What Do We Have to Know about PD-L1 Expression in Prostate Cancer? A Systematic Literature Review. Part 2: Clinic-Pathologic Correlations
Andrea Palicelli et al.
CELLS (2021)
Non-Muscle Invasive Bladder Cancer with Variant Histology: Biological Features and Clinical Implications
Francesca Sanguedolce et al.
ONCOLOGY (2021)
Immune Checkpoint Inhibitors in Urothelial Carcinoma: Recommendations for Practical Approaches to PD-L1 and Other Potential Predictive Biomarker Testing
Antonio Lopez-Beltran et al.
CANCERS (2021)
Performance of Different Diagnostic PD-L1 Clones in Head and Neck Squamous Cell Carcinoma
Julika Ribbat-Idel et al.
FRONTIERS IN MEDICINE (2021)
What Is New on Ovarian Carcinoma: Integrated Morphologic and Molecular Analysis Following the New 2020 World Health Organization Classification of Female Genital Tumors
Antonio De Leo et al.
DIAGNOSTICS (2021)
Significance of TP53 and immune-related genes to prostate cancer
Hang Huang et al.
TRANSLATIONAL ANDROLOGY AND UROLOGY (2021)
Identification of docetaxel-related biomarkers for prostate cancer
Yun Peng et al.
ANDROLOGIA (2021)
Solitary vulvar metastasis from early-stage endometrial cancer Case report and literature review
Vincenzo Dario Mandato et al.
MEDICINE (2021)
Gastrointestinal Manifestations in Systemic Mastocytosis: The Need of a Multidisciplinary Approach
Magda Zanelli et al.
CANCERS (2021)
EBV-Driven Lymphoproliferative Disorders and Lymphomas of the Gastrointestinal Tract: A Spectrum of Entities with a Common Denominator (Part 2)
Magda Zanelli et al.
CANCERS (2021)
Indolent T-Cell Lymphoproliferative Disorders of the Gastrointestinal Tract (iTLPD-GI): A Review
Francesca Sanguedolce et al.
CANCERS (2021)
EBV-Driven Lymphoproliferative Disorders and Lymphomas of the Gastrointestinal Tract: A Spectrum of Entities with a Common Denominator (Part 1)
Magda Zanelli et al.
CANCERS (2021)
Fetal Presentation of Mediastinal Immature Teratoma: Ultrasound, Autopsy and Cytogenetic Findings
Maria Paola Bonasoni et al.
DIAGNOSTICS (2021)
Biomarkers and cell-based models to predict the outcome of neoadjuvant therapy for rectal cancer patients
Aylin Alkan et al.
BIOMARKER RESEARCH (2021)
EZH2 inhibition activates a dsRNA-STING-interferon stress axis that potentiates response to PD-1 checkpoint blockade in prostate cancer
Katherine L. Morel et al.
NATURE CANCER (2021)
WD repeat domain 5 promotes chemoresistance and Programmed Death-Ligand 1 expression in prostate cancer
Qianghua Zhou et al.
THERANOSTICS (2021)
Mapping the binding sites of antibodies utilized in programmed cell death ligand-1 predictive immunohistochemical assays for use with immuno-oncology therapies
Nicola L. Lawson et al.
MODERN PATHOLOGY (2020)
Intraductal carcinomas of the salivary glands: systematic review and classification of 93 published cases
Andrea Palicelli
APMIS (2020)
What do we know about the cytological features of pure intraductal carcinomas of the salivary glands?
Andrea Palicelli
CYTOPATHOLOGY (2020)
Pembrolizumab for Treatment-Refractory Metastatic Castration-Resistant Prostate Cancer: Multicohort, Open-Label Phase II KEYNOTE-199 Study
Emmanuel S. Antonarakis et al.
JOURNAL OF CLINICAL ONCOLOGY (2020)
A pilot trial of pembrolizumab plus prostatic cryotherapy for men with newly diagnosed oligometastatic hormone-sensitive prostate cancer
Ashley E. Ross et al.
PROSTATE CANCER AND PROSTATIC DISEASES (2020)
Comparability of PD-L1 immunohistochemistry assays for non-small-cell lung cancer: a systematic review
Bregje M. Koomen et al.
HISTOPATHOLOGY (2020)
PT-112 in advanced metastatic castrate-resistant prostate cancer (mCRPC), as monotherapy or in combination with PD-L1 inhibitor avelumab: Findings from two phase I studies.
Alan Haruo Bryce et al.
JOURNAL OF CLINICAL ONCOLOGY (2020)
LRP11 activates β-catenin to induce PD-L1 expression in prostate cancer
Sishun Gan et al.
JOURNAL OF DRUG TARGETING (2020)
Immune profiling of human tumors identifies CD73 as a combinatorial target in glioblastoma
Sangeeta Goswami et al.
NATURE MEDICINE (2020)
Germinotropic lymphoproliferative disorder: a systematic review
Magda Zanelli et al.
ANNALS OF HEMATOLOGY (2020)
T-Cell Infiltration and Adaptive Treg Resistance in Response to Androgen Deprivation With or Without Vaccination in Localized Prostate Cancer
Aleksandar Z. Obradovic et al.
CLINICAL CANCER RESEARCH (2020)
PT-112 induces immunogenic cell death and synergizes with immune checkpoint blockers in mouse tumor models
Takahiro Yamazaki et al.
ONCOIMMUNOLOGY (2020)
Neoadjuvant rituximab modulates the tumor immune environment in patients with high risk prostate cancer
Stephen T. Ryan et al.
JOURNAL OF TRANSLATIONAL MEDICINE (2020)
Tumor Fusion Burden as a Hallmark of Immune Infiltration in Prostate Cancer
Marie-Claire Wagle et al.
CANCER IMMUNOLOGY RESEARCH (2020)
Loss of DNA mismatch repair proteins in prostate cancer
Meenal Sharma et al.
MEDICINE (2020)
Neoadjuvant PROSTVAC prior to radical prostatectomy enhances T-cell infiltration into the tumor immune microenvironment in men with prostate cancer
Houssein Abdul Sater et al.
JOURNAL FOR IMMUNOTHERAPY OF CANCER (2020)
p300/CBP inhibition enhances the efficacy of programmed death-ligand 1 blockade treatment in prostate cancer
Jinghui Liu et al.
ONCOGENE (2020)
Chemerin Reactivates PTEN and Suppresses PD-L1 in Tumor Cells via Modulation of a Novel CMKLR1-mediated Signaling Cascade
Keith Rennier et al.
CLINICAL CANCER RESEARCH (2020)
Impacts of combining anti-PD-L1 immunotherapy and radiotherapy on the tumour immune microenvironment in a murine prostate cancer model
Yiannis Philippou et al.
BRITISH JOURNAL OF CANCER (2020)
A phase II single-arm study of pembrolizumab with enzalutamide in men with metastatic castration-resistant prostate cancer progressing on enzalutamide alone
Julie N. Graff et al.
JOURNAL FOR IMMUNOTHERAPY OF CANCER (2020)
Endometrial Carcinomas with Intestinal-Type Metaplasia/Differentiation: Does Mismatch Repair System Defects Matter? Case Report and Systematic Review of the Literature
Laura Ardighieri et al.
JOURNAL OF CLINICAL MEDICINE (2020)
eEF2K enhances expression of PD-L1 by promoting the translation of its mRNA
Yu Wu et al.
BIOCHEMICAL JOURNAL (2020)
Biomarkers for immune checkpoint therapy targeting programmed death 1 and programmed death ligand 1
Jingjing Fan et al.
BIOMEDICINE & PHARMACOTHERAPY (2020)
Wee1 kinase inhibitor AZD1775 potentiates CD8+T cell-dependent antitumour activity via dendritic cell activation following a single high dose of irradiation
Bin Wang et al.
MEDICAL ONCOLOGY (2020)
Nivolumab Plus Ipilimumab for Metastatic Castration-Resistant Prostate Cancer: Preliminary Analysis of Patients in the CheckMate 650 Trial
Padmanee Sharma et al.
CANCER CELL (2020)
LncRNA KCNQ1OT1 sponges miR-15a to promote immune evasion and malignant progression of prostate cancer via up-regulating PD-L1
Qi-Hua Chen et al.
CANCER CELL INTERNATIONAL (2020)
Novel Long Non-coding RNA lncAMPC Promotes Metastasis and Immunosuppression in Prostate Cancer by Stimulating LIF/LIFR Expression
Wei Zhang et al.
MOLECULAR THERAPY (2020)
An Analysis of Isoclonal Antibody Formats Suggests a Role for Measuring PD-L1 with Low Molecular Weight PET Radiotracers
Junnian Wei et al.
MOLECULAR IMAGING AND BIOLOGY (2020)
Revisiting the PD-1 pathway
Nikolaos Patsoukis et al.
SCIENCE ADVANCES (2020)
Dramatic response to combination pembrolizumab and radiation in metastatic castration resistant prostate cancer
Harry J. Han et al.
THERAPEUTIC ADVANCES IN MEDICAL ONCOLOGY (2020)
Increased Tim-3 expression on TILs during treatment with the Anchored GM-CSF vaccine and anti-PD-1 antibodies is inversely correlated with response in prostate cancer
Xinji Zhang et al.
JOURNAL OF CANCER (2020)
Targeting Prostate Cancer Using Intratumoral Cytotopically Modified Interleukin-15 Immunotherapy in a Syngeneic Murine Model
Efthymia Papaevangelou et al.
IMMUNOTARGETS AND THERAPY (2020)
ADAM10 and ADAM17 cleave PD-L1 to mediate PD-(L)1 inhibitor resistance
Jacob J. Orme et al.
ONCOIMMUNOLOGY (2020)
Fructose-1,6-bisphosphatase loss modulates STAT3-dependent expression of PD-L1 and cancer immunity
Bo Wang et al.
THERANOSTICS (2020)
The Immune Landscape of Prostate Cancer and Nomination of PD-L2 as a Potential Therapeutic Target
Shuang G. Zhao et al.
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE (2019)
MLL3 enhances the transcription of PD-L1 and regulates anti-tumor immunity
Wei Xiong et al.
BIOCHIMICA ET BIOPHYSICA ACTA-MOLECULAR BASIS OF DISEASE (2019)
Phase I Study of the Indoleamine 2,3-Dioxygenase 1 (IDO1) Inhibitor Navoximod (GDC-0919) Administered with PD-L1 Inhibitor (Atezolizumab) in Advanced Solid Tumors
Kyung Hae Jung et al.
CLINICAL CANCER RESEARCH (2019)
Programmed death ligand 1 expression in prostate cancer cells is associated with deep changes of the tumor inflammatory infiltrate composition
Manuel Scimeca et al.
UROLOGIC ONCOLOGY-SEMINARS AND ORIGINAL INVESTIGATIONS (2019)
PD-L1 expression and deficient mismatch repair in ductal adenocarcinoma of the prostate
Claes Lindh et al.
APMIS (2019)
JQ1, a BET-bromodomain inhibitor, inhibits human cancer growth and suppresses PD-L1 expression
Kaisheng Liu et al.
CELL BIOLOGY INTERNATIONAL (2019)
Reduced T-cell Numbers and Elevated Levels of Immunomodulatory Cytokines in Metastatic Prostate Cancer Patients De Novo Resistant to Abiraterone and/or Enzalutamide Therapy
Sumanta K. Pal et al.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES (2019)
PD-L1 Expression in De Novo Metastatic Castration-sensitive Prostate Cancer
Roberto Iacovelli et al.
JOURNAL OF IMMUNOTHERAPY (2019)
Low Expression of miR-424-3p is Highly Correlated with Clinical Failure in Prostate Cancer
E. Richardsen et al.
SCIENTIFIC REPORTS (2019)
Targeting amphiregulin (AREG) derived from senescent stromal cells diminishes cancer resistance and averts programmed cell death 1 ligand (PD-L1)-mediated immunosuppression
Qixia Xu et al.
AGING CELL (2019)
Immunohistochemistry of immune checkpoint markers PD-1 and PD-L1 in prostate cancer
Meenal Sharma et al.
MEDICINE (2019)
CTHRC1 and PD-1/PD-L1 expression predicts tumor recurrence in prostate cancer
Qing Zhou et al.
MOLECULAR MEDICINE REPORTS (2019)
The Δ133p53β isoform promotes an immunosuppressive environment leading to aggressive prostate cancer
Marina Kazantseva et al.
CELL DEATH & DISEASE (2019)
Combination immunotherapy and radiotherapy causes an abscopal treatment response in a mouse model of castration resistant prostate cancer
Stephanie O. Dudzinski et al.
JOURNAL FOR IMMUNOTHERAPY OF CANCER (2019)
Sequential MR Image-Guided Local Immune Checkpoint Blockade Cancer Immunotherapy Using Ferumoxytol Capped Ultralarge Pore Mesoporous Silica Carriers after Standard Chemotherapy
Bongseo Choi et al.
SMALL (2019)
A tricky and rare cause of pulmonary eosinophilia: myeloid/lymphoid neoplasm with eosinophilia and rearrangement of PDGFRA
Magda Zanelli et al.
BMC PULMONARY MEDICINE (2019)
Immunogenicity of prostate cancer is augmented by BET bromodomain inhibition
Wendy Mao et al.
JOURNAL FOR IMMUNOTHERAPY OF CANCER (2019)
Distinct tumor microenvironments of lytic and blastic bone metastases in prostate cancer patients
Claire L. Ihle et al.
JOURNAL FOR IMMUNOTHERAPY OF CANCER (2019)
Overexpression of SOCS3 mediated by adenovirus vector in mouse and human castration-resistant prostate cancer cells increases the sensitivity to NK cells in vitro and in vivo
Tomomi Yoneda et al.
CANCER GENE THERAPY (2019)
Programmed Death Ligand 1 (PD-L1) Status and Tumor-Infiltrating Lymphocytes in Hot Spots of Primary and Liver Metastases in Prostate Cancer With Neuroendocrine Differentiation
Jost von Hardenberg et al.
CLINICAL GENITOURINARY CANCER (2019)
Expression of PD-L1 in tumor-associated nerves correlates with reduced CD8+ tumor-associated lymphocytes and poor prognosis in prostate cancer
Ru-Jun Mo et al.
INTERNATIONAL JOURNAL OF CANCER (2019)
Phosphorylated RB Promotes Cancer Immunity by Inhibiting NF-κB Activation and PD-L1 Expression
Xin Jin et al.
MOLECULAR CELL (2019)
Pregnancy-related decidualization of subcutaneous endometriosis occurring in a post-caesarean section scar: Case study and review of the literature
Cinzia D'Agostino et al.
PATHOLOGY RESEARCH AND PRACTICE (2019)
Tumor-infiltrating mesenchymal stem cells: Drivers of the immunosuppressive tumor microenvironment in prostate cancer?
Timothy E. Krueger et al.
PROSTATE (2019)
Identification of targets for prostate cancer immunotherapy
Antonios Papanicolau-Sengos et al.
PROSTATE (2019)
Specific zinc finger-induced methylation of PD-L1 promoter inhibits its expression
Xue Li et al.
FEBS OPEN BIO (2019)
Analysis of the Prevalence of Microsatellite Instability in Prostate Cancer and Response to Immune Checkpoint Blockade
Wassim Abida et al.
JAMA ONCOLOGY (2019)
PD-L1 Expression and CD8+ T-cell Infiltrate are Associated with Clinical Progression in Patients with Node-positive Prostate Cancer
Florent Petitprez et al.
EUROPEAN UROLOGY FOCUS (2019)
The Novel Combination of Nitroxoline and PD-1 Blockade, Exerts a Potent Antitumor Effect in a Mouse Model of Prostate Cancer
Naijin Xu et al.
INTERNATIONAL JOURNAL OF BIOLOGICAL SCIENCES (2019)
Role of ERCC1 expression in colorectal adenoma-carcinoma sequence and relation to other mismatch repair proteins expression, clinicopathological features and prognosis in mucinous and non-mucinous colorectal carcinoma
Abd AlRahman Mohammad Foda et al.
INDIAN JOURNAL OF PATHOLOGY AND MICROBIOLOGY (2019)
The prognostic value of tumor PD-L1 status in patients with metastatic prostate cancer
V. B. Matveev et al.
ONKOUROLOGIYA (2019)
The Immune Checkpoint Regulator PDL1 is an Independent Prognostic Biomarker for Biochemical Recurrence in Prostate Cancer Patients Following Adjuvant Hormonal Therapy
Heng Li et al.
JOURNAL OF CANCER (2019)
Small-Molecule Sigma1 Modulator Induces Autophagic Degradation of PD-L1
Christina M. Maher et al.
MOLECULAR CANCER RESEARCH (2018)
Cyclin D-CDK4 kinase destabilizes PD-L1 via cullin 3-SPOP to control cancer immune surveillance
Jinfang Zhang et al.
NATURE (2018)
Comprehensive Evaluation of Programmed Death-Ligand 1 Expression in Primary and Metastatic Prostate Cancer
Michael C. Haffner et al.
AMERICAN JOURNAL OF PATHOLOGY (2018)
Molecular Profiling of Pooled Circulating Tumor Cells from Prostate Cancer Patients Using a Dual-Antibody-Functionalized Microfluidic Device
Changqing Yin et al.
ANALYTICAL CHEMISTRY (2018)
Pembrolizumab for advanced prostate adenocarcinoma: findings of the KEYNOTE-028 study
A. R. Hansen et al.
ANNALS OF ONCOLOGY (2018)
Paratesticular seminoma: echographic features and histological diagnosis with review of the literature
Andrea Palicelli et al.
APMIS (2018)
Frequencies and expression levels of programmed death ligand 1 (PD-L1) in circulating tumor RNA (ctRNA) in various cancer types
Toshiyuki Ishiba et al.
BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS (2018)
MiR-195/-16 Family Enhances Radiotherapy via T Cell Activation in the Tumor Microenvironment by Blocking the PD-L1 Immune Checkpoint
Zhen Tao et al.
CELLULAR PHYSIOLOGY AND BIOCHEMISTRY (2018)
In vitro-induced M2 type macrophages induces the resistance of prostate cancer cells to cytotoxic action of NK cells
Lijun Xu et al.
EXPERIMENTAL CELL RESEARCH (2018)
Predictive Performance of Four Programmed Cell Death Ligand 1 Assay Systems on Nivolumab Response in Previously Treated Patients with Non-Small Cell Lung Cancer
Daichi Fujimoto et al.
JOURNAL OF THORACIC ONCOLOGY (2018)
Combined inhibition of JAK1,2/Stat3-PD-L1 signaling pathway suppresses the immune escape of castration-resistant prostate cancer to NK cells in hypoxia
Li-Jun Xu et al.
MOLECULAR MEDICINE REPORTS (2018)
ATM-JAK-PD-L1 signaling pathway inhibition decreases EMT and metastasis of androgen-independent prostate cancer
Lan Zhang et al.
MOLECULAR MEDICINE REPORTS (2018)
Inhibition of IL-6-JAK/Stat3 signaling in castration-resistant prostate cancer cells enhances the NK cell-mediated cytotoxicity via alteration of PD-L1/NKG2D ligand levels
Lijun Xu et al.
MOLECULAR ONCOLOGY (2018)
Adipocytes affect castration-resistant prostate cancer cells to develop the resistance to cytotoxic action of NK cells with alterations of PD-L1/NKG2D ligand levels in tumor cells
Lijun Xu et al.
PROSTATE (2018)
Concurrent, but not sequential, PD-1 blockade with a DNA vaccine elicits anti-tumor responses in patients with metastatic, castration-resistant prostate cancer
Douglas G. McNeel et al.
Oncotarget (2018)
RANKL blockade improves efficacy of PD1-PD-L1 blockade or dual PD1-PD-L1 and CTLA4 blockade in mouse models of cancer
Elizabeth Ahern et al.
ONCOIMMUNOLOGY (2018)
Unicystic high-grade intraductal carcinoma of the parotid gland: cytological and histological description with clinic-pathologic review of the literature
Andrea Palicelli et al.
APMIS (2018)
Reproducibility of PD-L1 immunohistochemistry interpretation across various types of genitourinary and head/neck carcinomas, antibody clones, and tissue types
Chiyun Wang et al.
HUMAN PATHOLOGY (2018)
Immunogenomic analyses associate immunological alterations with mismatch repair defects in prostate cancer
Daniel Nava Rodrigues et al.
JOURNAL OF CLINICAL INVESTIGATION (2018)
Immune infiltrates and PD-L1 expression in treatment-naive acinar prostatic adenocarcinoma: an exploratory analysis
Elan Hahn et al.
JOURNAL OF CLINICAL PATHOLOGY (2018)
Quick efficacy seeking trial (QuEST1): a novel combination immunotherapy study designed for rapid clinical signal assessment metastatic castration-resistant prostate cancer
Jason M. Redman et al.
JOURNAL FOR IMMUNOTHERAPY OF CANCER (2018)
Intravascular NK/T-cell lymphoma, Epstein-Barr virus positive with multiorgan involvement: a clinical dilemma
Magda Zanelli et al.
BMC CANCER (2018)
STAT3 Inhibition Combined with CpG Immunostimulation Activates Antitumor Immunity to Eradicate Genetically Distinct Castration-Resistant Prostate Cancers
Dayson Moreira et al.
CLINICAL CANCER RESEARCH (2018)
Cancer immunotherapy using PolyPurine Reverse Hoogsteen hairpins targeting the PD-1/PD-L1 pathway in human tumor cells
Miriam Marlene Medina Enriquez et al.
PLOS ONE (2018)
Activity of durvalumab plus olaparib in metastatic castration-resistant prostate cancer in men with and without DNA damage repair mutations
Fatima Karzai et al.
JOURNAL FOR IMMUNOTHERAPY OF CANCER (2018)
Immunotherapy utilizing the combination of natural killer- and antibody dependent cellular cytotoxicity (ADCC)-mediating agents with poly (ADP-ribose) polymerase (PARP) inhibition
Kathleen E. Fenerty et al.
JOURNAL FOR IMMUNOTHERAPY OF CANCER (2018)
Positive Pelvic Lymph Nodes in Prostate Cancer Harbor Immune Suppressor Cells To Impair Tumor-reactive T Cells
Vidit Sharma et al.
EUROPEAN UROLOGY FOCUS (2018)
Imaging PD-L1 Expression with ImmunoPET
Charles Truillet et al.
BIOCONJUGATE CHEMISTRY (2018)
Carcinosarcoma of the prostate: case report with molecular and histological characterization
Samanta Salvi et al.
INTERNATIONAL JOURNAL OF BIOLOGICAL MARKERS (2018)
Immunogenomics: A Negative Prostate Cancer Outcome Associated with TcR-γ/δ Recombinations
Yaping N. Tu et al.
CANCER MICROENVIRONMENT (2018)
Inflammatory cytokines IL-17 and TNF-α up-regulate PD-L1 expression in human prostate and colon cancer cells
Xun Wang et al.
IMMUNOLOGY LETTERS (2017)
PD-L1 Immunohistochemistry Assays for Lung Cancer: Results from Phase 1 of the Blueprint PD-L1 IHC Assay Comparison Project
Fred R. Hirsch et al.
JOURNAL OF THORACIC ONCOLOGY (2017)
Effective combinatorial immunotherapy for castration-resistant prostate cancer
Xin Lu et al.
NATURE (2017)
VISTA is an inhibitory immune checkpoint that is increased after ipilimumab therapy in patients with prostate cancer
Jianjun Gao et al.
NATURE MEDICINE (2017)
Primary histiocytic sarcoma presenting as diffuse leptomeningeal disease: Case description and review of the literature
Magda Zanelli et al.
NEUROPATHOLOGY (2017)
SHP2 negatively regulates HLA-ABC and PD-L1 expression via STAT1 phosphorylation in prostate cancer cells
Zhuqing Liu et al.
ONCOTARGET (2017)
5T4 oncofoetal glycoprotein: an old target for a novel prostate cancer immunotherapy
Federica Cappuccini et al.
ONCOTARGET (2017)
The prognostic role of immune checkpoint markers programmed cell death protein 1 (PD-1) and programmed death ligand 1 (PD-L1) in a large, multicenter prostate cancer cohort
Nora Ness et al.
ONCOTARGET (2017)
Comprehensive immunohistochemical analysis of PD-L1 shows scarce expression in castration-resistant prostate cancer
Christian D. Fankhauser et al.
Oncotarget (2017)
Sensitive detection of PD-L1 expression on circulating epithelial tumor cells (CETCs) could be a potential biomarker to select patients for treatment with PD-1/PD-L1 inhibitors in early and metastatic solid tumors
Dorothea Sonja Schott et al.
ONCOTARGET (2017)
Genomic Analysis of Tumor Microenvironment Immune Types across 14 Solid Cancer Types: Immunotherapeutic Implications
Yu-Pei Chen et al.
THERANOSTICS (2017)
Enhancement of PSMA-Directed CAR Adoptive Immunotherapy by PD-1/PD-L1 Blockade
Inna Serganova et al.
MOLECULAR THERAPY-ONCOLYTICS (2017)
Chromosome 9p copy number gains involving PD-L1 are associated with a specific proliferation and immune-modulating gene expression program active across major cancer types
Jan Budczies et al.
BMC MEDICAL GENOMICS (2017)
PD-1/PD-L1 blockade enhances the efficacy of SA-GM-CSF surface-modified tumor vaccine in prostate cancer
Xiaojun Shi et al.
CANCER LETTERS (2017)
Expression of PD-L1 in Hormone-naive and Treated Prostate Cancer Patients Receiving Neoadjuvant Abiraterone Acetate plus Prednisone and Leuprolide
Carla Calagua et al.
CLINICAL CANCER RESEARCH (2017)
Immune Characterization of the Programmed Death Receptor Pathway in High Risk Prostate Cancer
Wesley Baas et al.
CLINICAL GENITOURINARY CANCER (2017)
A unique case of bilateral ovarian splenosis and review of the literature
Maria Giulia Disanto et al.
APMIS (2017)
PD-L1 blockade in preclinical models of PTEN-deficient prostate cancer
Marco A. De Velasco et al.
CANCER RESEARCH (2017)
Armed Oncolytic Adenovirus-Expressing PD-L1 Mini-Body Enhances Antitumor Effects of Chimeric Antigen Receptor T Cells in Solid Tumors
Kiyonori Tanoue et al.
CANCER RESEARCH (2017)
The Immune Checkpoint Regulator PD-L1 Is Highly Expressed in Aggressive Primary Prostate Cancer
Heidrun Gevensleben et al.
CLINICAL CANCER RESEARCH (2016)
Magnitude of PD-1, PD-L1 and T Lymphocyte Expression on Tissue from Castration-Resistant Prostate Adenocarcinoma: An Exploratory Analysis
Francesco Massari et al.
TARGETED ONCOLOGY (2016)
Tungiasis in Italy: An imported case of Tunga penetrans and review of the literature
Andrea Palicelli et al.
PATHOLOGY RESEARCH AND PRACTICE (2016)
Orbital meningeal melanocytoma: Histological, immunohistochemical and molecular characterization of a case and review of the literature
Andrea Palicelli et al.
PATHOLOGY RESEARCH AND PRACTICE (2016)
CXCL12 promoter methylation and PD-L1 expression as prognostic biomarkers in prostate cancer patients
Diane Goltz et al.
ONCOTARGET (2016)
Activation of the PD-1/PD-L1 immune checkpoint confers tumor cell chemoresistance associated with increased metastasis
Madison Black et al.
ONCOTARGET (2016)
Early evidence of anti-PD-1 activity in enzalutamide-resistant prostate cancer
Julie N. Graff et al.
ONCOTARGET (2016)
PD-L1 promoter methylation is a prognostic biomarker for biochemical recurrence-free survival in prostate cancer patients following radical prostatectomy
Heidrun Gevensleben et al.
ONCOTARGET (2016)
Antitumor vaccination of prostate cancer patients elicits PD-1/PD-L1 regulated antigen-specific immune responses
Brian T. Rekoske et al.
ONCOIMMUNOLOGY (2016)
Potential role of nuclear PD-L1 expression in cell-surface vimentin positive circulating tumor cells as a prognostic marker in cancer patients
Arun Satelli et al.
SCIENTIFIC REPORTS (2016)
Characterization of 1577 Primary Prostate Cancers Reveals Novel Biological and Clinicopathologic Insights into Molecular Subtypes
Scott A. Tomlins et al.
EUROPEAN UROLOGY (2015)
Immunosuppressive plasma cells impede T-cell-dependent immunogenic chemotherapy
Shabnam Shalapour et al.
NATURE (2015)
Paucity of PD-L1 expression in prostate cancer: innate and adaptive immune resistance
A. M. Martin et al.
PROSTATE CANCER AND PROSTATIC DISEASES (2015)
IL-27 induces the expression of IDO and PD-L1 in human cancer cells
Grazia Carbotti et al.
ONCOTARGET (2015)
Methylome-wide Sequencing Detects DNA Hypermethylation Distinguishing Indolent from Aggressive Prostate Cancer
Jeffrey M. Bhasin et al.
CELL REPORTS (2015)
PD-L1 is highly expressed in Enzalutamide resistant prostate cancer
Jennifer L. Bishop et al.
ONCOTARGET (2015)
Radiation-Induced Modulation of Costimulatory and Coinhibitory T-Cell Signaling Molecules on Human Prostate Carcinoma Cells Promotes Productive Antitumor Immune Interactions
Michael B. Bernstein et al.
CANCER BIOTHERAPY AND RADIOPHARMACEUTICALS (2014)
The PD-1/PD-Ls pathway and autoimmune diseases
Suya Dai et al.
CELLULAR IMMUNOLOGY (2014)
Association of PD-1, PD-1 Ligands, and Other Features of the Tumor Immune Microenvironment with Response to Anti-PD-1 Therapy
Janis M. Taube et al.
CLINICAL CANCER RESEARCH (2014)
Langer Mesomelic Dysplasia in Early Fetuses: Two Cases and a Literature Review
Fabrizio Ambrosetti et al.
FETAL AND PEDIATRIC PATHOLOGY (2014)
Tumor stroma-derived factors skew monocyte to dendritic cell differentiation toward a suppressive CD14+ PD-L1+ phenotype in prostate cancer
Lisa K. Spary et al.
ONCOIMMUNOLOGY (2014)
Unleashing the immune system: PD-1 and PD-Ls in the pre-treatment tumor microenvironment and correlation with response to PD-1/PD-L1 blockade
Janis M. Taube
ONCOIMMUNOLOGY (2014)
PD-1 Blockade Augments Th1 and Th17 and Suppresses Th2 Responses in Peripheral Blood From Patients With Prostate and Advanced Melanoma Cancer
John Dulos et al.
JOURNAL OF IMMUNOTHERAPY (2012)
Safety, Activity, and Immune Correlates of Anti-PD-1 Antibody in Cancer
Suzanne L. Topalian et al.
NEW ENGLAND JOURNAL OF MEDICINE (2012)
Simultaneous inhibition of two regulatory T-cell subsets enhanced Interleukin-15 efficacy in a prostate tumor model
Ping Yu et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2012)
分享论文
